Citi downgraded Calliditas Therapeutics (CALT) to Neutral from Buy with a $39 price target after Asahi Kasei (AHKSY) announced an agreement to acquire Calliditas for about $39 per ADS or about $1.1B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- CHMP Endorses Calliditas’ Kinpeygo for IgAN
- Calliditas Therapeutics downgraded to Hold from Buy at Jefferies
- Calliditas Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Calliditas Therapeutics downgraded to Hold from Buy at Stifel
- Calliditas Therapeutics presents data at European Renal Association Congress